Applied BioMath Announces Two-Year Strategic Partnership with Xilio Therapeutics

Applied BioMath announced a two-year strategic partnership with Xilio Therapeutics.  Applied BioMath will provide a variety of services related to mathematical modeling, simulation, analysis, and visualization, which include systems pharmacology, quantitative systems pharmacology, experiment prioritization and design, and traditional and mechanistic pharmacokinetic (PK) / pharmacodynamic (PD) modeling, in support of Xilio's preclinical and clinical drug development projects. 

John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath Said: We are thrilled to announce this next phase of our partnership with Xilio Therapeutics, We really enjoy being part of the project teams, working on exciting projects and science, and helping to better inform decisions.  We take pride in partnerships such as these as they are evidence that our prior collaborations with our partners provided high value.

Applied BioMath employs a rigorous fit-for-purpose model development process which quantitatively integrates knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms.  Applied BioMath's approach employs proprietary algorithms and software that were designed specifically for systems pharmacology model development, simulation, and analysis. 

Jennifer O'Neil, PhD, Vice President, Translational Oncology at Xilio Therapeutics Said: Our previous collaborations with Applied BioMath informed the advancement of our preclinical candidates, We look forward to continuing to work closely with Applied BioMath and incorporate their approach into more of our projects.

SOURCE Applied BioMath

Related Posts

Subscribe Our Newsletter